Brind.

Benzinga provided stock analysis on Zymeworks on September 3, 2025.

1 report, 1 independent Updated Sep 3

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Zymeworks Benzinga

Keep exploring

The entities involved

Zymeworks
company
- Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.Mon 11:01
- Zymeworks is leveraging Irish tax attributes as part of its deal with Mylan.Mon 11:01
Benzinga
American news channel
- Benzinga reported on the recent stock price activity of SpaceX.Mon 02:14
- Benzinga reported analyst expectations for Jabil.Mon 02:08

Related events

Benzinga is reporting on companies that are listed on the Nasdaq stock exchange.Jun 16
Benzinga reported on the financial performance of Salesforce, Inc. on May 27, 2026.Jun 7
Benzinga reports on Wabash National Corporation stock.Sep 22
Benzinga reported on the financial performance of company RH.Jun 11

Coverage

Newest first; wire copies grouped

Sep 3BenzingaZymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit Zymeworks Inc. (NASDAQ:ZYME) on Tuesday decided to voluntarily discontinue clinical development of ZW171, a